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Summary 
Members of the myocyte enhancer factor-2 (MEFS) 
family of MADS domain transcription factors cannot 
induce myogenesis in transfected fibroblasts, but 
when coexpressed with the myogenic basic-helix- 
loop-helix (bHLH) proteins MyoD or myogenin they 
dramatically increase the extent of myogenic conver- 
sion above that seen with either myogenic bHLH factor 
alone. This cooperativity required direct interactions 
between the DNA-binding domains of MEF2 and the 
myogenic bHLH factors, but only one of the factors 
needed a transactivation domain, and only one of the 
factors needed to be bound to DNA. These interactions 
allow either factor toactivate transcription through the 
others binding site and reveal a novel mechanism for 
indirect activation of gene expression via protein-pro- 
tein interactions between the DNA-binding domains of 
heterologous classes of transcription factors. 
Introduction 
Myocyte enhancer factor-2 (MEF2) was originally identi- 
fied as a muscle-specific DNA-binding activity that was 
induced when skeletal myoblasts differentiated into myo- 
tubes(Gossett etal., 1989; reviewed by Olson et al., 1995). 
The MEF2-binding site, CTA(A/T)4TAG, is found in thecon- 
trol regions of numerous muscle-specific genes and has 
been demonstrated to be important for skeletal and car- 
diac muscle gene expression (Olson et al., 1995 and refer- 
ences therein). MEFP DNA-binding activity is encoded by 
four genes in humans and mice, referred to as mef2A 
through mef2D (Pollock and Treisman, 1991; Yu et al., 
1992; Breitbart et al., 1993; Martin et al., 1994) whose 
products bind DNA as homodimers and heterodimers. 
MEF2 proteins contain a 56 amino acid MADS domain, 
named for the first four proteins in which this domain 
was identified: minichromosome maintenance 1 (MCMl), 
which regulates mating-specific genes in yeast, AGA- 
MOUS and DEFICIENS, which have homeotic functions 
in flower development, and serum response factor (SRF), 
which regulates serum-inducible and muscle gene expres- 
sion (reviewed by Shore and Sharrocks, 1995). The four 
mef2 gene products, also referred to as RSRFs (for related 
to SRFs) (Pollock and Treisman, 1991), share greater than 
85% amino acid identity within the MADS domain and an 
adjacent 27 amino acid region referred to as the MEF2 
domain, but they are divergent in their C-termini. This ho- 
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mology in the MADS and MEF2 domains is also observed 
in the single MEF2 protein in Drosophila (Lilly et al., 1994; 
Nguyen et al., 1994; Taylor et al., 1995) and several MEF2 
proteins in Xenopus (Chambers et al., 1992; Wong et al., 
1994). 
Expression of the mef2 genes marks early myogenic 
lineages during embryogenesis (Edmondson et al., 1994; 
Chambers et al., 1992). MEF2C is the first member of 
the family to be expressed in the mouse, with transcripts 
appearing in the precardiac mesoderm at day 7.5 postcoi- 
turn (PC). Subsequently, the other mef2 genes are ex- 
pressed throughout the developing heart. MEF2C is ex- 
pressed in skeletal muscle cells within the somite 
myotome beginning at about day 9.0 pc, and the other 
mef2 genes are expressed soon thereafter. The mef2 
genes also show specific expression patterns in the devel- 
oping brain (Lyons et al., 1995). After birth, MEF2A, 
MEF2B, and MEF2D transcripts are expressed ubiqui- 
tously (Pollock and Treisman, 1991; Yu et al., 1992; Leifer 
et al., 1993; Martin et al., 1993, 1994; McDermott et al., 
1993; Breitbart et al., 1993), whereas MEFPC transcripts 
are restricted to skeletal muscle, brain, and spleen (Martin 
et al., 1993; McDermott et al., 1993). Despite the wide- 
spread expression of mef2 mRNAs in adult tissues and 
established cell lines, MEF2 DNA-binding activity is highly 
enriched in muscle cells and neurons. 
Recent evidence suggests that MEF2 and myogenic 
basic-helix-loop-helix (bHLH) proteins act within a regula- 
tory network that establishes the differentiated phenotype 
of skeletal muscle. The four myogenic bHLH proteins, 
MyoD, myogenin, myf5, and MRM, can each activate the 
program for skeletal muscle differentiation when intro- 
duced into a variety of nonmuscle cell types (Olson, 1990; 
Emerson, 1993; Wright, 1992; Lassar and Munsterberg, 
1994). The bHLH motif mediates dimerization of the myo- 
genie factors with ubiquitous HLH proteins such as E12, 
E47, and HEB, resulting in heterodimeric complexes that 
bind to the E box consensus DNA sequence (CANNTG) 
(Murre et al., 1989; Brennan and Olson, 1990; Lassar et 
al., 1991; Hu et al., 1992) associated with many muscle- 
specific genes. Paradoxically, however, myogenic bHLH 
proteins can also activate transcription of muscle-specific 
genes that lack E boxes in their control regions. The mech- 
anism responsible for this type of indirect gene activation 
by myogenic bHLH proteins has not been clarified. 
Forced expression of myogenin or MyoD in nonmuscle 
cells induces MEF2 DNA-binding activity, suggesting that 
MEF2 lies within a regulatory cascade downstream of the 
myogenic bHLH proteins (Martin et al., 1993; Chambers 
et al., 1994; Cserjesi and Olson, 1991; Lassar et al., 1991). 
However, a MEF2 site within the myogenin promoter has 
been shown to be essential for myogenin transcription in 
cultured muscle cells and mouse embryos (Edmondson 
et al., 1992; Cheng et al., 1993; Yee and Rigby, 1993). 
Similarly, the Xenopus myoDa gene is regulated by a 
MEF2 site that overlaps with the TATA box (Leibham et 
al., 1994). Forced expression of MEF2A in fibroblasts has 
also been reported to induce the expression of myogenin 
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Figure 1. lmmunostaining of Transfected lOT% Ceils for MHC and 
MEFPC 
lOT% cells were transiently transfected with expression vectors en- 
coding MyoD, myogenin, and MEFPC as indicated. Cultures were 
transferredfromgrowthmedium(GM)2daysaftertransfectiontodiffer- 
entiation medium (DM) for an additional 6 days and were then stained 
with Hoechst (A-F), anti-MHC (A-H), or anti-MEFPC (G and H). No 
MHC staining was observed with MEFPC or with the bHLH region of 
myogenin (Myo-bHLH) alone. Note the presence of MEF2C in the 
nuclei of cells that did not express MHC (G), unless MyoD was also 
present (H). 
and MyoD and to initiate muscle differentiation (Kaushal 
et al., 1994). Together, these data suggest that MEF2 and 
myogenic bHLH proteins are involved in reciprocal regula- 
tory circuits that amplify and maintain the expression of 
both families of regulators. 
The functions of vertebrate MEF2 factors have not yet 
been analyzed by loss-of-function assays. However, loss- 
of-function mutations in the single mef2gene in Drosophila 
prevent differentiation of somatic, cardiac, and visceral 
musclecells(Lillyet al., 1995; Bour et al., 1995; Ranganay- 
akulu et al., 1995), demonstrating that MEF2 is necessary 
for the differentiation of multiple muscle cell types. The 
MyoD homolog Nautilus (Michelson et al., 1990; Paterson 
et al., 1991) appears in myoblasts within the somatic mus- 
cle lineage in D-men mutant embryos, but it is unable to 
activate the expression of muscle structural genes, sug- 
gesting that D-MEFP is required for Nautilus activity. 
In this study, we demonstrate that MEF2 factors act 
as coregulators to potentiate the myogenic activities of 
myogenic bHLH proteins. This cooperativity requires inter- 
Table 1. MEFP Synergizes with Myogenic bHLH Proteins to 
Induce Myogenesis 
Percentage 
Constructs Expressing MHC 
MyoD a.1 f 1.3 
MyoD plus MEFPC 23.2 f 3.2 
MEFPC 0 
MEFPC plus El2 0 
MyoD plus MEF2C(R24L) 19.3 * 1.2 
MyoD plus MEF2C(K31 L) 17.3 * 0.9 
MyoD plus MEF2C(A40-57) 9.5 f 0.6 
MyoD plus MEF2C(A58-85) 8.9 f 0.5 
MyoD plus MEF2C(l-117) 14.7 f 0.8 
MyoD plus MEFPC(l-117-VP16) 28.5 f 1.5 
MyoD plus MEFPA 15.6 k 0.5 
MyoD plus MEFSD 15.9 f 0.9 
MEFPA 0 
MEFPD 0 
MyoD plus SRF 7.5 f 1.1 
MyoD-ElPbasic 0 
MyoD-E12basic plus MEFZC 0 
MyoD-El2(AT) 6.8 f 0.9 
MyoD-E12(AT) plus MEFPC 21.4 f 1.3 
Myogenin 4.6 + 0.8 
Myogenin plus MEFPC 11.5 + 0.7 
Myogenin plus MEF2C(R24) 9.1 f 1.1 
Myogenin plus MEF2C(A58-85) 3.8 f 0.8 
Myogenin(T87D) plus MEFPC 0 
Myo-bHLH 0 
Myo-bHLH plus MEFPC 8.8 f 0.9 
Myo-bHLH plus MEFPC(l-117) 0 
1 OT% cells were transiently transfected with 6 pg of MyoD or myogenin 
and 2 pg of MEF2 expression vectors. Cells were transferred lo DM 
2 days after transfection and were assayed for MHC expression by 
immunostaining 6 days later. Values represent the percentage of total 
cells under each condition that expressed MHC and represent the 
average f SEM of three independent experiments. In those cases 
where theproteinsfailed todisplaymyogenicactivity, theywereshown 
to be expressed by immunostaining. 
action between the DNA-binding domains (DBDs) of MEF2 
and myogenic bHLH factors, which allows these two 
classes of transcription factors to activate synergistically 
the transcription of genes containing a binding site for only 
one of the two factors. 
Results 
MEFSC Synergizes with Myogenic bHLH Factors 
to Induce Myogenesis 
To begin to define the role of MEF2 in muscle-specific 
gene activation, we tested whether forced expression of 
MEF2C was sufficient to induce myogenesis in transfected 
lOTI/ cells. In contrast with a previous report (Kaushal 
et al., 1994) that concluded that MEFP can activate the 
complete myogenic program, expression of MEFPC alone 
yielded no myosin heavy chain (MHC)-positive cellsfollow- 
ing transient or stable transfection (Figure 1E). The ex- 
pression of MEF2C in transfected cells was confirmed by 
immunostaining (Figure 1 G). 
We next tested whether MEF2C might cooperate with 
MyoD or myogenin to induce myogenesis. Indeed, when 
MEFC was expressed with either MyoD or myogenin, in- 
MEF2 and MyoD Are Coactivators of Myogenesis 
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Figure 2. Expression of MHC Protein in Transfected lOT% Cells 
iOT% cells were transiently transfected with expression vectors en- 
coding MyoD, myogenin. and MEFZ, as indicated. Cultures were trans- 
ferred from GM 2 days after transfection to DM for an additional 6 
days. Cells were then harvested, and MHC protein was detected by 
Western blot analysis in aliquots of cell extract containing equivalent 
quantities of protein. The MHC band was quantitated by densitometry 
and expressed relative to the amount of MHC protein in cells 
transfected with myogenrn 
duction of myogenesis was synergistic (compare Figures 
1A and 1 B; Table 1). Under these conditions, we observed 
a 3- to 4-fold increase in the number of MHC-positive ceils. 
We also observed a substantial increase in the number of 
multinucleate myotubes that were present, whereas with 
either myogenic bHLH factor alone the majority of MHC- 
positive cells were mononucleate (Figure 1; Table 1). Like 
MEFPC, MEF2A and MEF2D were unable to induce myo- 
genesis alone, but cooperated with MyoD to induce myo- 
genesis (Table 1). The magnitude of the synergism be- 
tween MEF2 and myogenic bHLH proteins is probably 
underestimated in these assays, because in the presence 
of MEF2 most of the MHC-positive cells were multinucle- 
ate myotubes, which were scored as single positive cells. 
To quantitate further the magnitude of the synergism 
between myogenic bHLH proteins and MEF2, we mea- 
sured MHC protein expression by Western blot analysis 
of extracts from transiently transfected 1OTM cells (Figure 
2). MEF2C alone was unable to induce MHC expression, 
whereas, in the presence of myogenin or MyoD, MHC pro- 
tein was induced to a level about 8- to lo-fold higher than 
with either myogenic bHLH factor alone. 
Synergism between MEF2 and Myogenic bHLH 
Factors Is Mediated by Their DBDs 
To begin to define the region within the myogenic bHLH 
factors that cooperates with MEF2, we tested the ability 
of a myogenin mutant (Myo-bHLH) lacking the N- and 
C-terminal activation domains to induce myogenesis with 
MEF2C. This mutant dimerizes with E proteins and binds 
DNA, but it lacks myogenic activity (Schwarz et al., 1992). 
However, in the presence of MEF2, this mutant efficiently 
induced myogenesis in 1 OT% cells (compare Figures 1 C 
and 1 D; Table 1). These results demonstrate that syner- 
gism between myogenin and MEF2C is mediated by the 
bHLH region of myogenin and show that MEF2C can con- 
fer myogenic activity to the bHLH region of myogenin. 
To define the domains of MEF2C that were required 
for synergism with myogenic bHLH factors, we expressed 
MyoD and myogenin with various MEF2C mutants that are 
defective for DNA binding, dimerization, or transcriptional 
activation (J. D. M. and E. N. O., unpublished data). The 
MEF2C deletion mutant l-l 17 (Figure 3A), which lacks 
the C-terminal transactivation domain and is unable to acti- 
vate a MEF2-dependent reporter, cooperated with the 
myogenic bHLH factors to initiate myogenesis, but it was 
slightly weaker than the wild-type protein (Table 1) sug- 
gesting that the transcriptional activation domain en- 
hanced the synergism, but was dispensable. We observed 
no myogenic conversion when mutant l-l 17 was ex- 
pressed together with the myogenin deletion mutant Myo- 
bHLH, indicating that one of the two factors needed an 
activation domain. The mutant l-l 17-VP16, in which the 
transcription activation domain of MEF2C was replaced 
with that of herpesvirus virion protein 16 (VP16) (Figure 
3A), was unable to induce myogenesis independently, but 
showed stronger synergistic activity than wild-type MEF2C 
(Table 1). Together, these results demonstrate that MEF2 
is a cofactor for myogenic bHLH proteins and that a tran- 
scriptional activation domain is required in either MEF2 
or a myogenic bHLH protein, but not in both, to activate 
endogenous muscle-specific genes in 1 OTX cells. 
To determine whether DNA binding by MEF2C was re- 
quired for synergism with myogenic bHLH factors, we ex- 
amined the activity of two MEF2C mutants, R24L and 
K31 L, which contain point mutations in the MADS domain 
and fail to bind DNA (Figure 38; J. D. M. and E. N. O., 
unpublished data). Surprisingly, both of these mutants 
were able to cooperate with MyoD and myogenin to induce 
myogenesis (Figure 1 F; Table 1). We further defined the 
region within the N-terminus of MEF2C that mediates syn- 
ergism with myogenic bHLH factors by testing two MEF2C 
deletion mutants, A40-57 and A58-85, which lack por- 
tions of the MADS box and MEF2 domains and are unable 
todimerizeor bind DNA(J. D. M. and E. N. O., unpublished 
data). Both of these mutants failed to increase the expres- 
sion of MHC over that induced by myogenin or MyoD 
alone. Together, these results suggest that the MADS and 
MEF2 domains are required for cooperativity between 
MEF2C and myogenic bHLH factors, but DNA binding and 
transcriptional activation by MEF2C are not required. 
Because SRF has been implicated in muscle gene acti- 
vation (Walsh, 1989; Sartorelli et al., 1990; Lee et al., 
1992), we tested whether it might also synergize with 
MyoD to induce myogenesis. When SRF was coexpressed 
with MyoD, however, we observed no increase in MHC- 
positive cells over the number seen with myogenin alone 
(Table 1). Thus, although SRF and MEF2 share homology 
in their MADS domains, this homology is insufficient to 
mediate synergism between SRF and the myogenic fac- 
tors in a myogenic conversion assay. 
Because synergism between myogenic bHLH factors 
and MEF2C did not require DNA binding by MEF2C, we 
tested whether a myogenin mutant that was unable to bind 
DNA might be able to synergize with MEF2C (Table 1). 
The myogenin mutant T87D, which contains an aspartic 
acid in place of a threonine at codon 87 and fails to bind 




activate myogenesis in the absence (data not shown) or 
presence (Table 1) of MEF2C. These results indicate that 
the myogenic bHLH factor must be bound to DNA via the 
E box to initiate the endogenous myogenic program in 
1 OTVZ cells. 
Previous studies demonstrated that two amino acids, 
alanine-threonine, in the center of the DBDs of myogenic 
bHLH proteins were required for muscle gene activation 
(Davis et al., 1990; Brennan et al., 1991). If these residues 
were replaced with asparagines, which are found at the 
corresponding positions in the DBDs of E proteins, the 
mutant myogenic factors retained the ability to bind DNA, 
but they lost the ability to activate myogenesis. Con- 
versely, if alanine and threonine were introduced into the 
corresponding positions of E12, they conferred on El2 
the ability to activate muscle gene expression (Davis and 
Weintraub, 1992). Because these myogenic amino acids 
do not affect DNA binding but are essential for myogenic 
activity, it has been hypothesized that they mediate inter- 
action with a cofactor required for muscle gene activation 
(Davis et al., 1990; Brennan et al., 1991; Weintraub et al., 
1991). To determine whether these same myogenic amino 
acids were required for cooperativity with MEF2, we tested 
whether the mutant MyoD-El2basic, which contains the 
basic region of El2 in place of that of MyoD, could syner- 
gize with MEF2 to activate myogenesis. In contrast with 
wild-type MyoD, this mutant failed to synergize with 
MEF2C (Table 1). However, if alanine-threonine was rein- 
troduced into the El2 basic region in the mutant MyoD- 
El 2(AT), which has been shown to restore myogenic activ- 
ity to MyoD (Davis and Weintraub, 1992) the ability to 
Figure 3. Deletion and Point Mutants of 
MEFZC 
(A) Schematic representation of MEFPC and 
deletion mutants. For mutants A40-57, A58- 
85. and A70-85, in-frame deletions were intro- 
duced that removed the indicated amino acids. 
Mutant l-l 17 lacks the C-terminal transactiva- 
tion domain. Mutant l-l 17-VP16 contains the 
MADS and MEFP domains fused in-frame to 
the transactivation domain of VP16. 
(B) The amino acid sequence of the MADS and 
MEFP domains of mouse MEFPC is shown, 
with the names of mutants at the left. A dash 
indicates no change at that position. Basic 
amino acids within the DSD are indicated in 
black, and the hydrophobic dimerization do- 
main is stippled. 
synergize with MEF2 was also restored (Table 1). These 
results demonstrate that the myogenic amino acids in the 
DBD of MyoD are required for cooperativity with MEF2. 
Interaction between MEFSC and 
MyogeninlEl2 Heterodimers 
To investigate further the basis for the cooperation be- 
tween MEF2 and myogenic bHLH proteins, we tested 
whether these proteins physically interacted. Myogenin 
and El 2 were translated in a rabbit reticulocyte lysate sep- 
aratelyand in conjunction with the MEF2C deletion mutant 
l-105, which contained a Flag epitope tag. 35S-labeled 
translation products were then immunoprecipitated with 
an anti-Flag antibody and resolved by SDS-polyacryl- 
amide gel electrophoresis (SDS-PAGE). When MEF2C 
was cotranslated with either myogenin or E12, there was 
no evidence for protein-protein interactions (Figure 4, 
lanes 6 and 7). However, when MEF2C was cotranslated 
with myogenin and E12, both bHLH proteins were coim- 
munoprecipitated with MEFC (Figure 4, lane 5). These 
results demonstrate that MEF2 binds specifically to the 
myogeninlE12 heterodimer, but not to myogenin or El2 
homodimers. 
Mapping of Interactions of MEFSC 
and MyogeninlElS Using a 
Tri-Hybrid System 
To determine whether MEFPC interacted with myogenin/ 
El2 heterodimers in vivo and to map the domains of 
MEF2C that mediated this interaction, we employed a 
GAL4 DBD-dependent reporter system, in which the bHLH 
MEFZ and MyoD Are Coactivators of Myogenesls 
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Figure 4. Coimmunoprecipitation of MEF2C with MyogeninlE12 
MEF2C deletion mutant l-105 containing a Flag epitope tag at its 
C-terminus was translated in a rabbit reticulocyte lysate in the pres- 
ence or absence of myogenin and El2, as indicated. Translation reac- 
tions were then immunoprecipitated with anti-Flag antibody and 
[35S]methionine-labeled proteins were analyzed by SDS-PAGE. The 
in vitro translation products of myogenin and El2 are shown in lanes 
1 and 2. Lanes 3-7 show coimmunoprecipitations. Myogenin and El2 
are only coimmunoprecipitated together with MEF2C (lane 5). 
regions of myogenin and El2 were fused to the DBD of 
yeastGAL4(Figure5A). When introduced into lOTI/ cells, 
these chimeric proteins, referred to as GAL(DBD)-Myo 
and GAL(DBD)-E12, failed to activate expression of the 
GAL4-dependent reporter gene pG5El bCAT (Figure 58, 
lanes 1 and 4). When GAL(DBD)-Myo was expressed with 
El 2, chloramphenicol acetyltransferase (CAT) expression 
was induced as a result of heterodimerization between 
the bHLH of myogenin and that of El2 (lane 6). The El2 
expression plasmid used for these experiments encoded 
an El 2 deletion mutant lacking part of the N-terminal tran- 
scription activation domain and therefore results in only 
weak transactivation. We used this mutant so that interac- 
tions with MEMC could be more readily detected above 
the transcriptional activity of GAL(DBD)-Myo plus El2 
(see below). If full-length El2 was coexpressed with 
GAL(DBD)-Myo, much higher activation was observed 
(Chakraborty et al., 1992). We detected no expression 
of the reporter gene when either GAL(DBD)-Myo or 
GAL(DBD)-El2 was coexpressed separately with MEFPC 
(Figure 58, lanes 3 and 5). However, if GAL(DBD)-Myo 
and El2 were expressed together with MEFPC, there was 
an -g-fold increase in reporter gene expression over the 
level seen without MEF2C (Figure 58, lane 7). In contrast, 
MEF2C did not enhance reporter gene expression in the 
presenceofGAL(DBD)-E12andEl2(Figure5B,lane3)or 
in the presence of GAL(DBD)-Myo (lane 5). These results 
suggested that MEFPC was able to interact in vivo, specifi- 
cally with the myogeninlE12 heterodimer and not with an 
E12/E12 homodimer or with myogenin alone. 
To map the region of MEF2C that was required for inter- 
action with myogenin/E12, we tested several MEF2C mu- 
tants in the above assay. The deletion mutant l-l 17 dem- 
onstrated the ability to interact with myogeninlE12, 
although the magnitudeof activation wasless than with the 
full-length protein (Figure 58, lane 8). This is presumably 
because mutant l-l 17 lacks an activation domain. How- 
ever, it retains the ability to dimerize and may recruit the 
low level of endogenous MEFP protein in 1 OT% cells. Alter- 
natively, there may be an additional cofactor that recog- 
nizes the complex of MEF2-myogenin/E12. Fusion of 
the VP16 activation domain to MEF2C l-l 17, to create 
l-l 17-VP16, resulted in greater than 35fold activation 
of the reporter (Figure 5B, lane 9). If El2 was omitted 
from the assay, l-l 17-VP16 only weakly interacted with 
GAL(DBD)-Myo (Figure 5B, lane 10). This weak activation 
probably occurs because of the low level of endogenous 
E proteins in lOT% cells that dimerize with GAL(DBD)- 
Myo. Deletion of the MEF2 domain in mutants A58-85 
and A70-85 severely diminished interaction of MEF2C 
with myogeninlE12 (Figure 5C, lanes 4 and 5). Similarly, 
the mutant A40-57, which lacked part of the MADS box, 
interacted with myogeninlE12 less effectively than wild- 
type MEFPC (Figure 5C, lane 3). 
The above results demonstrated that the determinants 
of the interaction between MEF2C and myogeninlE12 
were located within both the MADS and MEFP domains 
of MEF2C. To define further the residues that mediated 
this interaction, we tested several MEF2 site-directed mu- 
tants in thisassay. Mutation of Lys31, which had a minimal 
effect on synergism between MyoD and MEF2C in myo- 
genie conversion (Table l), also had only a minimal effect 
on interaction with GAL(DBD)-Myo plus El 2 (Figure 5C, 
lane 6). We tested 12 separate point mutants of the MADS 
box in the tri-hybrid assay, yet no single mutation led to 
a loss in the ability of MEF2C to interact with myogeninl 
El 2 (data not shown). These data suggest that the inter- 
active surface is distributed throughout the MADS box of 
MEF2C. The interaction between MEF2C and myogeninl 
El2 did not require MEF2 DNA-binding activity, since mu- 
tant STDMD59-63, which dimerized but failed to bind 
DNA, interacted with myogeninlE12 as effectively as the 
wild-type protein (Figure 5C, lane 8). We also introduced 
mutations into the MEFP domain to map the amino acids 
that were required for interaction with myogeninlE12. Mu- 
tants STDMD59-63 and VLL65-67, containing mutations 
toward the N-terminal end of the MEF2 domain, interacted 
with myogeninlEl2 as efficiently as wild-type MEF2C (Fig- 
ure 5C, lanes 8 and 9), whereas the more C-terminal mu- 
tants NEPH73-76 and ESRT77-80 did not interact (lanes 
10 and 11). suggesting that the C-terminal end of the MEF2 
domain plays a major role in mediating interaction be- 
tween MEFPC and myogeninlE12. 
MEF2 and Myogenic bHLH Proteins Can Activate 
Transcription through Each 
Other’s Binding Sites 
The above experiments demonstrated that MEFP was able 
to interact directly with myogeninlE12 heterodimers and 
that synergism between MEF2 and myogenic bHLH pro- 
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determine whether MEF2 was able to synergize with myo- 
genin to activate transcription through the E box-binding 
site, we tested whether the myogenin mutant Myo-bHLH 
could cooperate with MEF2 to transactivate the E box- 
dependent reporter 41%TKCAT, which contains four tan- 
dem copies of the right E box from the muscle creatine 
kinase (MCK) enhancer upstream of the thymidine kinase 
(TK) promoter linked to CAT (Weintraub et al., 1990). This 
reporter does not respond to MEF2 or the highly potent 
MEM mutant l-l 17-VP16, confirming that it contains no 
MEF2-binding sites (Figure 6A, lane 8). Myo-bHLH was 
also unable to activate expression of 41%TKCAT because 
this mutant lacks the N- and C-terminal transactivation 
domains (Figure 6A, lane 3). Similarly, an N-terminal dele- 
tion mutant of El2 lacking the transcription activation do- 
1 
Figure 5. Interactions Between MEFLC and 
MyogeninlEl2 Detected by a Tri-Hybrid Assay 
lOTr/z cells were transiently transfected bycal- 
cium phosphate precipitation with pG5El b- 
CAT and expression vectors encoding 
GAL4(DBD)-E12, GAL4(DBD)-Myo, an N-ter- 
minal deletion mutant of E12, and wild-type 
(WT) and mutant MEFPC, as indicated. Cells 
were shifted from GM to DM 24 hr after trans- 
fection. Cells were harvested 48 hr later, and 
CAT activities were determined in aliquots of 
cell extract containing equivalent amounts of 
total cellular protein. (A) shows a schematic 
representation of the assay. (B) and (C) show 
the results of transfection assays with different 
expression vectors. The plasmids included in 
each transfection assay are indicated by (plus). 
Values are expressed as the fold activation of 
the reporter gene relative to the level of expres- 
sion observed with GAL4(DBD)-Myo and E12. 
Values represent the averagesof four indepen- 
dent experiments. 
s 
main was unable to activate this reporter alone or in the 
presence of Myo-bHLH (Figure 6A, lanes 2 and 4). How- 
ever, a high level of transactivation was observed when 
the three factors, Myo-bHLH, E12, and MEF2C, were 
combined (Figure 6A, lane 9). This transactivation was 
dependent on the E boxes in the reporter gene because 
the TK promoter alone was nonresponsive (data not 
shown). Transcriptional activation was also dependent on 
all three factors; any two of the factors showed no tran- 
scriptional activity(Figure 6A, lanes4,6, and 7). The MEF2 
mutant, K31 L, which was unable to bind DNA, synergized 
with Myo-bHLH plus El2 as efficiently as wild-type MEF2 
(Figure 6A, lane lo), confirming that this type of synergism 
did not require binding of MEF2 to DNA. Together, these 
results demonstrate that MEF2 can transfer its transcrip- 
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tion-activating potential to the heterologous DBD of the 
myogeninlEl2 heterodimer to activate transcription 
through the E box. 
We also tested whether myogenic bHLH proteins could 
activate transcription of a MEFPdependent gene that 
lacked E boxes. MEF2C deletion mutant 1-117, which 
lacks the C-terminal transactivation domain, was unable 
to activate the MEFBdependent reporter pE102MEF2 x 2 
CAT(Figure 6A, lane2), which contains two tandem copies 
of the MEF2 site from the MCK enhancer upstream of the 
embryonic MHC basal promoter (Figure 6B). As was the 
case for the E box-dependent reporter, any combination 
of two factors was unable to activate the MEFP-dependent 
reporter (Figure 6B, lanes 3-5). However, when myogenin 
plus El2 was expressed with the DBD of MEF2C, which 
lacks transcriptional activity on its own, the reporter gene 
was activated to high levels (Figure 6B, lane 6). Coopera- 
tive activation by the three factors together was also ob- 
served with a reporter containing four copies of the MEF2 
site upstream of the TK promoter, whereas no activation 
was observed with the TK promoter alone (data not 
shown). Mutation of the MEF2 sites in pE102MEF2x2 
CAT also eliminated responsiveness to the combination 
of MEF2C plus myogenin/E12 (data not shown). These 
Figure 6. MEF2 and Myogenic bHLH Factors 
ActivateTranscription of Reporter Genes Lack- 
ing Their Binding Sites 
lOTI/ cells were transiently transfected with 
the E box- and MEF2-dependent reporter 
genes 4WTKCAT (A) and pE102MEF2 x 2CAT 
(B), respectively, and expression vectors en- 
coding wild-type or mutant MEFZ, myogenic 
bHLH factors, and E12, as indicated. CAT ac- 
tivity in cell extracts was determined as de- 
scribed in Experimental Procedures. Values 
are expressed as the fold induction of CAT ac- 
tivity above that observed with each reporter 
gene alone The diagram beside each panel 
illustrates how transcriptional activation of the 
reporter gene via protein-protein interactions 
may occur. 
results demonstrate that myogenic bHLH proteins can in- 
duce transcription of a gene lacking an E box by transfer- 
ring activation to the DBD of MEF2 when it is bound to 
its site. 
Finally, we tested the MyoD mutant, MyoD-E12basic 
containing the El2 basic region to determine whether it 
could synergize with MEF2 mutant l-l 17 to activate tran- 
scription through the MEF2 site. Despite the fact that this 
MyoD mutant containsafunctional transcription activation 
domain (Weintraub et al., 1991), it was unable to transfer 
its activating potential through MEF2 to activate the MEF2- 
dependent reporter(Figure 6B, lane7). However, introduc- 
tion of the myogenic amino acids, alanine-threonine, into 
the DBD of this mutant restored the ability to cooperate 
with the DBD of MEF2 to activate transcription (MyoD- 
E12(AT) in Figure 6B, lane 8). Thus, the same residues 
in the MyoD basic region that are required for activation 
of the myogenic program are required for MyoD-mediated 
activation of transcription through the MEF2 site. 
Discussion 
The results of this study demonstrate that MEF2 factors 
collaborate with myogenic bHLH proteins to activate mus- 
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cle gene expression and that this cooperativity is mediated 
by direct protein-protein interactions between the DBDs 
of these heterologous classes of transcription factors. This 
type of cooperativity provides an explanation for the ab- 
sence of muscle in Drosophila embryos lacking MEFP and 
for previous mutational analyses of the basic regions of 
myogenic bHLH factors, which suggested that they re- 
quired a cofactor that recognized the DBD for activation 
of myogenesis. 
Synergy between MEF2 and Myogenic bHLH 
Proteins Is Mediated by Interactions 
between Their DBDs 
Our initial observation was that MEF2 factors alone were 
incapable of initiating the myogenic program in trans- 
fected lOT% cells, but that MEFPA, MEF2C or MEF2D 
could augment the myogenic activity of MyoD or myo- 
genin. These results differ from those of a previous study, 
which reported that MEF2A wasa myogenicdetermination 
factor that could induce the complete myogenic program 
in transfected fibroblasts with an efficiency comparable 
with that of MyoD (Kaushal et al., 1994). We have been 
unable to detect expression of muscle structural genes or 
the formation of multinucleate myotubes following tran- 
sient or stable transfection of lOT% cells with MEF2A, 
MEFPC, or MEF2D, even when using the same expression 
plasmid used by Kaushal and coworkers. The basis for 
the discrepancy between the two studies is unclear. 
The synergy between MEF2 and myogenic bHLH pro- 
teins suggested that these factors physically interacted. 
Indeed, coimmunoprecipitation and tri-hybrid assays 
demonstrated that MEF2 recognized myogeninlE12 heter- 
odimers. Only when all three proteins were present to- 
gether was a physical interaction apparent. These analy- 
ses demonstrated that the MADSlMEFP domains of 
MEF2C specifically interacted with the heterodimer formed 
between the bHLH regions of myogenin and El2 and dem- 
onstrated aprecisecorrelation between the ability of MEF2 
mutants to interact with myogeninlE12 in vivo and their 
ability to cooperate in myogenic conversion. This is consis- 
tent with previous studies that showed that MEF2 binds 
DNA cooperatively with myogenin in myotube nuclear ex- 
tracts (Funk and Wright, 1992). A previous study in which 
interactions between MyoD and MEF2 were analyzed us- 
ing GST fusion proteins (Kaushal et al., 1994) concluded 
that only the MADS domain was sufficient for interaction 
with MyoD and that El 2 was not necessary for the interac- 
tion. 
MEF2 and Myogenic bHLH Factors Cross-Activate 
through Each Other’s Binding Sites 
A myogenin mutant containing only the bHLH region was 
unable to activate the E box-dependent reporter in the 
presence of a truncated El2 protein. However, when wild- 
type MEFPC containing an intact transactivation domain 
was expressed with the bHLH regions of myogenin and 
E12, synergistic activation of transcription was observed. 
Furthermore, a mutant MEF2C protein (K31L) that was 
incapable of binding DNA by itself was still able to interact 
with the Myo-bHLHIE12 heterodimerto activate transcrip- 
tion synergistically through the E box. MEF2C expressed 
separately with the bHLH regions of either myogenin or 
El2 was unable to potentiate transcription through the E 
box. Together, these results suggest that the heterodimer 
of Myo-bHLHIEl2 binds to the multimerized E box sites 
to act as a platform on which MEF2C interacts to activate 
transcription. 
A MEFPC deletion mutant lacking a transactivation do- 
main was unable to activate transcription through the 
MEF2 site by itself or with either El2 or myogenin alone. 
Onlythecombinationof MEF2C l-l 17 and myogeninlE12 
together resulted in transcriptional activation, demonstrat- 
ing that the heterodimer of myogeninlE12 could interact 
with MEF2 bound to DNA. These results provide an expla- 
nation for previous studies that demonstrated that MEF2 
and myogenic bHLH factors synergistically activate tran- 
scription of muscle gene promoters containing binding 
sites for only one of the factors (Naidu et al., 1995; Black 
et al., 1995). 
The model generated from these in vitro expression ex- 
periments is supported by the in vivo results using the 
myogenic conversion assay. In this assay, the bHLH re- 
gion of myogenin by itself is unable to induce myogenesis. 
However, when wild-type MEF2C containing a transactiva- 
tion domain is expressed with the myogenin bHLH, myo- 
genie conversion is restored. This suggests that, in vivo, 
MEFPC can specifically interact with the myogenin bHLH 
domain at E box target sites to activate transcription by 
protein-protein association and the recruitment of the 
transactivation domain of MEF2C. This also suggests that 
an activation domain is required in only one component 
of the complex between MEF2 and myogenic bHLH pro- 
teins for the myogenic program to be executed. 
When tested in the myogenic conversion assay, MyoD 
and MEF2 synergized to activate myogenesis without the 
need for exogenous E proteins. Previous studies demon- 
strated that E proteins are required for MyoD function and 
that the level of endogenous E proteins in IOTX cells is 
sufficient to support myogenic conversion (Lassar et al., 
1991). In contrast, when MyoD and MEF2 were tested 
for their ability to synergize on artificial reporters, it was 
essential that exogenous El2 also be provided. These 
results suggest that E proteins are limiting for activation 
of exogenous reporter genes that are present at high copy 
number. 
Multiple Mechanisms for Muscle Gene Activation by 
MEF2 and Myogenic bHLH Factors 
Our results demonstrate that MEF2 and myogenic bHLH 
factors can transfer transcriptional activity through one 
another’s DBDs when only one of the two factors is bound 
directly to DNA. Thus, the DBDs of MEF2 and myogenic 
bHLH factors play dual roles in the control of muscle gene 
transcription by mediating DNA sequence recognition and 
protein-protein interactions. The DBDs of MEF2 and myo- 
genie bHLH factors are also able to discriminate among 
different members of each class of transactivators. 
The interaction between MEF2 and the myogenic bHLH 
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proteins requires only the bHLH domain, and myogenic 
conversion by the trimeric complexes was dependent on 
the two myogenic amino acids, alanine-threonine, in the 
basic region of MyoD. It has been hypothesized that these 
amino acids mediate interaction with a coregulator re- 
quired for muscle gene activation (Davis et al., 1990; Bren- 
nan et al., 1991; Davis and Weintraub, 1992). Our results 
are consistent with the possibility that MEF2 is an essential 
coregulator through which the myogenic bHLH factors in- 
duce muscle gene transcription. The crystal structure of 
MyoD bound to DNA indicates that the myogenic residues 
in the MyoD basic region lie within the major groove of 
the DNA and are thus inaccessible for direct interaction 
with MEF2 (Ma et al., 1994). However, these residues ap- 
pear to be required for a conformational change in MyoD 
that may create the recognition surface for MEF2 inter- 
action. 
Further evidence implicating MEF2 asan essential core- 
gulator of muscle gene expression has been demon- 
strated by genetic analyses of mef2 in Drosophila (Lilly et 
al., 1995; Bour et al., 1995; Ranganayakulu et al., 1995). 
Loss-of-function mutations of Dmef2 prevent muscle cell 
differentiation, but they do not affect myoblast specifica- 
tion. In D-mef2 mutant flies, the myoD homolog nautilus 
is expressed normally in somatic muscle cell precursors, 
but muscle structural genes are not expressed. Thus, D- 
MEF2 may be essential for Nautilus function in somatic 
muscle cells. 
Together, our results support the model for MEF2 regu- 
lation of muscle genes shown in Figure 7. According to 
this model, MEF2 factors act as coregulators that mediate 
the myogenic activity of myogenic bHLH proteins. Assum- 
ing this to be the case, there would need to be MEF2 
activity in nonmyogenic cells in which the myogenic bHLH 
proteins can induce myogenesis. In fact, the existence of 
MEF2 factors in lOT% and other nonmyogenic cell types 
has been documented (Pollock and Treisman, 1991; 
Buchberger et al., 1994). There is also a low level of 
MEFPD protein in myoblasts that could collaborate with 
myogenic bHLH proteins to initiate the differentiation pro- 
gram (Breitbart et al., 1993). Previous studies have dem- 
onstrated that myogenic bHLH proteins can induce MEF2 
expression (Cserjesi and Olson, 1991; Lassar et al., 1991; 
Martin et al., 1993) which would further amplify muscle 
gene expression once the program has been initiated. 
Binding of MEF2 to the promoters of myogenic bHLH 
genes would also result in amplification and maintenance 
of their expression (Edmondson et al., 1992; Cheng et al., 
1993; Yee and Rigby, 1993; Leibham et al., 1994; Black 
et al., 1995; Naidu et al., 1995). MEFP can also activate E 
box-independent target genes by binding directly to MEF2 
sites in the control regions of those genes. In these cases, 
myogenic bHLH proteins could also activate these genes 
through protein-protein interactions with MEF2. In addi- 
tion, MEF2 can collaborate with myogenic bHLH proteins 
to activate expression of genes that are controlled by E 
boxes and MEF2 sites or it can act through myogenic 
bHLH proteins to activate E box-dependent genes that 
lack MEF2 sites. 
Inducing 
Signal 
AmDllffcation I I 
Figure 7. Possible Mechanisms for Muscle Gene Activation by Myo- 
genie bHLH Proteins and MEF2 
Myogenic bHLH factors are expressed in myoblasts in response to 
an initial inducing signal. Myogenic bHLH factors, probably in collabo- 
ration with a low level of MEF2 activity in myoblasts, can induce MEF2 
expression. MEFP binds the control regions of several myogenic bHLH 
genes, amplifying and maintaining their expression. Myogenic bHLH 
proteins activate E box-dependent genes that also contain MEF2 
sites. MEF2 can also act indirectly to activate E box-dependent genes 
by interacting with myogenic bHLH proteins. MEF2 can regulate mus- 
cle genes that lack E boxes in their control regions; MyoDlElP hetero- 
dimers may also activate these genes by protein-protein mteractions 
with MEFP. Interactions between MEFP and MyoD/EiZ may also pro- 
vide a mechanism for linking muscle-specific promoters and en- 
hancers 
Our demonstration that myogenic bHLH factors can ac- 
tivate transcription through the MEF2 site by interacting 
with the DBD of MEF2 may explain how myogenic bHLH 
factors induce the expression of muscle-specific genes 
that lack E boxes in their control regions. It is also interest- 
ing to point out that several muscle-specific genes appear 
to contain MEF2 sites embedded within their TATA boxes 
(Leibham et al., 1994; Grayson et al., 1995). Thus, binding 
of MEF2 to these elements may recruit myogenic bHLH 
factors to the promoters (Figure 7). This type of recruitment 
may provide a general mechanism for enhancer-promoter 
communication through which transcription factors at a 
distal enhancer are brought into contact with the promoter 
by interaction with heterologous transcription factors 
bound at or near the TATA box. 
How do the interactions between myogenic bHLH and 
MEF2 factors result in synergistic activation of muscle 
gene expression? As discussed above, previous muta- 
tional analyses provided strong evidence for the existence 
of a factor that recognized, and conferred myogenic activ- 
ity to, the basic regions of myogenic bHLH proteins. Based 
on our results, we propose that MEF2 is this factor and 
that it recognizes the bHLH regions of myogenic bHLH 
proteins when they are dimerized with E proteins. We favor 
a model in which all three proteins, MEF2, myogenic bHLH 
protein, and E12, create a specific conformation when as- 
sociated in a multiprotein complex that interacts with the 
transcriptional machinery more efficiently than any of the 
individual factors. The synergism between these factors 
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could result from a specific recognition event between the 
multiprotein complex and a component of the transcrip- 
tional machinery or it could result from a concerted reac- 
tion in which the assembly of the three factors stabilizes 
a transcriptional complex. Previous studies with MyoD 
showed that its transcription activation domain was 
masked in solution and suggested that its exposure re- 
quired the association of a cofactor that recognized the 
MyoD basic region (Weintraub et al., 1991). This type of 
allosteric activation of MyoD by MEF2 could also account 
for the synergism between these factors. 
MEF2 as a Coregulator of Gene Expression in Other 
Lineages 
The ability of MEF2 to cooperate with myogenic bHLH 
proteins is especially intriguing because other MADS box 
proteins have been shown to regulate cell-specific tran- 
scription as a consequence of their interactions with posi- 
tive and negative factors. MCMl , for example, acts in con- 
junction with two coregulators, al and a2, to regulate cell 
type-specific transcription in yeast (Herskowitz, 1989), 
and SRF interacts with a wide range of proteins to regulate 
serum-inducible transcription (Shore and Sharrocks, 
1995). 
The finding that MEF2 acts as a cofactor for myogenic 
bHLH proteins, but does not itself activate the skeletal 
muscle differentiation program, is consistent with the ap- 
pearance of MEF2 factors in cell types other than skeletal 
muscle. Members of the MEF2 family are expressed at 
high levels, for example, in cardiac and smooth muscle 
cells and neurons and, as discussed above, at low levels 
in several other cell types. Therefore, we propose that 
within the skeletal muscle lineage, MEF2 acts as a potenti- 
ator of the activity of the myogenic bHLH factors, but it 
does not independently specify cell fate. Whether MEFP 
can also interact with other cell-specific bHLH proteins 
remains to be determined. 
Experimental Procedures 
Transfections and Plasmids 
Transfections were performed as described previously (Martin et al., 
1993). We used 10 ng of the pE102MEF2 x PCAT reporter construct 
(Vu et al., 1992) along with 5 @g of the MEFPC test construct and 1 
fig of pRSVpGAL to control for transfection efficiency. Plasmid 
pE102MEF2 x 2CAT contains two MEFP sites from the MCK enhancer 
located upstream of the minimal promoter from the emb-MHC gene, 
which drives the expression of the CAT reporter gene. 
MEFPC deletion and point mutants will be described elsewhere (J. D. 
M. and E. N. O., unpublished data). The following MyoD and myogenin 
mutants were used. MyoD-E12basic contained the El2 basic region 
in place of the MyoD basic region; this mutant binds DNA, but cannot 
activate myogenesis (Davis et al., 1990). MyoD-E12(AT) contains two 
myogenic amino acids, alanine-threonine, in place of asparagine- 
asparagine in the basic region of MyoD-E12basrc; these residues re- 
store myogenic activity (Davis and Weintraub, 1992). Myogenin T67D 
contains an aspartic acid in place of Thr-87 in the basic region; this 
mutant dimerizes with E proteins, but fails to bind DNA (Brennan et 
al., 1991). Myogenin bHLH, previously referred to as DM4-791136- 
224, lacks amino acids 4-79 and 136-224, but contains the bHLH 
region (Schwarz et al., 1992). The El2 expression vector, EMSV-E12, 
contains a partial E72 cDNA, referred to as E12R (Murre et al., 1989) 
which was cloned with an initiating methionine codon into pEMSV. 
The EMSV-SW expression vector was a gift from M. Gilman (Ariad 
Pharmaceuticals). 
10TYz Cell Myogenic Conversion and lmmunofluorescence 
To assess the ability of MEFP to convert lOT% fibroblasts into myo- 
tubes (alone or in combination with a myogenic bHLH protein), we 
performed transient transfections. IOTVz fibrobfasts were grown to 
60% confluence in 6 cm dishes and transfected as described above 
with 6 pg of EMSV-MyoD (Davis et al., 1967) or EMSV-myogenin 
(Edmondson and Olson, 1989) and 2 ug of pCDNAI-MEFPC, when 
both were used together. If EMSV-MyoD was to be assessed alone, 
2 ng of pCDNAl/amp vector was also included to control for possible 
squelching effects. If pCDNAI-MEFZC alone was to be assessed, 
6 pg of EMSV plasmid was also added. After 8 hr, the cells were 
transferred to DMEM plus 2% horse serum (differentiation medium 
[DM]) and maintained under these conditions for 6 days, with media 
changes occurring every 2 days. 
lmmunostaining for MHC was performed as described previously 
(Edmondson and Olson, 1989). For MEFPC nuclear immunostaining, 
rabbit polyclonal MEFZC antiserum was added in blocking buffer to- 
gether with the anti-myosin at a I:250 dilution. This was then detected 
by adding TAITC-conjugated horse, anti-rabbit antiserum at a I:400 
dilution with the secondary FITC-conjugated goat, and anti-mouse anti- 
serum. Blue nuclear staining for DNA was performed with 0.5 ug/ml 
of bisbenzimide in PBS for 15 min, followed by three rinses with PBS. 
For assessing myogenic conversion of fibroblasts to myotubes, goat 
anti-mouse-conjugated horseradish peroxidase (HRP) was used as the 
secondary antibody to allow for visual quantitation of myosin-positive 
cells. 
Western Blotting 
lOTr/z cells were transfected with MyoD, MyoD and MEFPC, MEFPC, 
myogenin, or myogenin and MEFPC and subjected to the same differ- 
entiation protocol as outlined above. After 6 days in DM, the cells were 
harvested for Western blot analysis of total MHC accumulation. The 
cells were lysed in 40 nl of cracking buffer (4 M urea, 0.5% SDS, 0.5% 
NP-40, 100 mM Tris [pH 7.41, 5 mM EDTA) and analyzed by SDS- 
PAGE. The primary antibody was a mouse monoclonal anti-myosin 
fast MY-32 (Sigma, St. Louis, MO) used at a 1:lOOO dilution. Detection 
was performed using the ECL kit (Amersham, Buckinghamshire, En- 
gland) and required a secondary HRP-conjugated antibody (goat anti- 
mouse HRP; 1:lOOO). The results were quantitated by densitometry. 
In Vitro Translations and Coimmunoprecipitations 
Interactions between MEFPC and myogeninlE12 were assessed by 
immunoprecipitation of in vitro translation products myogenin and El2 
with a truncated MEFPC construct (amino acids I-105). The truncated 
MEFPC construct contained a Flag (Kodak IBI, New Haven, CT) epi- 
tope so that anti-Flag antibody could be used for specific immunopre- 
cipitation according to the conditions recommended by the manufac- 
turer (Kodak IBI). The precipitated products were subjected to SDS- 
PAGE and autoradiography. 
Tri-Hybrid Assay 
To measure the ability of MEFPC to interact with the bHLH region of 
myogenin, we employed a tri-hybrid-like assay. C3HiOTr/z cells were 
maintained and transfected as described previously (Black et al., 
1995). Cells were transfected with the GALCdependent reporter plas- 
mid pG5EI bCAT and either GAL(DBD)-Myoor GAL(DBD)-El2 to me- 
diate binding to the GAL4 sites in the reporter. GAL(DBD)-Myo and 
GAL(DBD)-El2 each contain the DBD of GAL4 (amino acids 1-147) 
fused to either the bHLH region of myogenin or E12, respectively. We 
transfected 5 ng of each construct. In transfections in which all three 
expression plasmids were not transfected along with the reporter, 5 
ng of the appropriate parental expression plasmid was cotransfected 
such that in each transfection 20 ug of plasmid DNA was used. Follow- 
ing transfection, cells were maintained in growth medium for 24 hr 
and were then transferred to DM for 48 hr before harvesting. CAT 
assays for this analysis were performed as described elsewhere (Black 
et al., 1995). 
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